DBV Technologies Reports Third Quarter 2025 Financial Results

Strategic Insights -

DBV Technologies, a clinical-stage biopharmaceutical company, reported financial results for the third quarter of 2025, highlighting a significant increase in research and development expenses. The company's unaudited financial statements show a cash and cash equivalents balance of $69.8 million as of September 30, 2025, with a net increase of $37.4 million compared to December 31, 2024.

The company's operating income increased to $5.0 million for the nine months ended September 30, 2025, up from $3.6 million in the same period last year. However, net loss for the nine months ended September 30, 2025, was $102.1 million, compared to a net loss of $90.9 million for the nine months ended September 30, 2024.

DBV Technologies also announced the establishment of an equity offering program, the ATM Program, which enables the company to offer and sell American Depositary Shares from time to time. The company has received approximately $30 million from the issuance of 11,538,460 ordinary shares under the ATM Program, with estimates suggesting that its cash and cash equivalents are sufficient to fund its operations into the third quarter of 2026.

Key Takeaways:

  • DBV Technologies reported a cash and cash equivalents balance of $69.8 million as of September 30, 2025, with a net increase of $37.4 million compared to December 31, 2024.
  • The company's operating income increased to $5.0 million for the nine months ended September 30, 2025, up from $3.6 million in the same period last year.
  • Net loss for the nine months ended September 30, 2025, was $102.1 million, compared to a net loss of $90.9 million for the nine months ended September 30, 2024.
  • DBV Technologies established an equity offering program, the ATM Program, to offer and sell American Depositary Shares from time to time.
  • The company received approximately $30 million from the issuance of 11,538,460 ordinary shares under the ATM Program.
  • Estimates suggest that DBV Technologies' cash and cash equivalents are sufficient to fund its operations into the third quarter of 2026.
  • The company's research tax credit increased to $5.0 million in the nine months ended September 30, 2025, compared to $3.6 million in the same period last year.
  • DBV Technologies' net cash flow used in operating activities decreased by $6.2 million to $86.0 million for the nine months ended September 30, 2025, compared to $92.2 million in the same period last year.

Statistics:

  • Cash and cash equivalents balance: $69.8 million as of September 30, 2025.
  • Net increase in cash and cash equivalents: $37.4 million compared to December 31, 2024.
  • Operating income: $5.0 million for the nine months ended September 30, 2025.
  • Net loss: $102.1 million for the nine months ended September 30, 2025.
  • Research tax credit: $5.0 million in the nine months ended September 30, 2025.
  • Net cash flow used in operating activities: $86.0 million for the nine months ended September 30, 2025.

Sources:

  • DBV Technologies, "DBV Technologies Reports Third Quarter 2025 Financial Results," October 28, 2025.
  • DBV Technologies, Condensed Consolidated Financial Statements, September 30, 2025 (unaudited).
  • DBV Technologies, Condensed Consolidated Statements of Operations, September 30, 2025 (unaudited).